Clinical Commander

Back to dossier
neonatal.hypoglycemia.v1PRODUCTION
neonatal.hypoglycemia.v1

Neonatal Hypoglycemia

pediatricsacuteneonatalpediatric
Hard-required inputs
0 / 12
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Frame by postnatal age (transitional <48 h vs persistent >48 h per PES 2015), GA cohort (late preterm 35-36 wk vs term), birth weight percentile (SGA <10th, LGA >90th).

Inputs
3
Actions
0
Advance rule
Set
Advance when

Cohort + postnatal age + percentile classified

Patient inputs (15)

Insulin, C-peptide, beta-hydroxybutyrate, free fatty acids, lactate, ammonia, cortisol, growth hormone — drawn AT hypoglycemia event for differential (PES 2015)

IDM cohort has highest hypoglycemia risk in first 12 h (Adamkin 2011)

Perinatal stress drives hypoglycemia via increased glucose utilization + impaired counter-regulation

KATP-channel mutations (ABCC8, KCNJ11), GLUD1, GCK — diazoxide-responsive vs -unresponsive subtypes

Tachycardia + diaphoresis are sympathetic features of hypoglycemia

Apnea / irregular breathing can be hypoglycemia manifestation

Hypothermia worsens hypoglycemia by increasing glucose utilization

Late preterm (35-36 wk) is a key at-risk cohort; <35 wk is broader NICU concern

SGA (<10th percentile) and LGA (>90th percentile) are independent risk factors

First 48 h vs > 48 h drives threshold target (2.6 vs 3.3 mmol/L); transitional vs persistent classification

POC glucose is screening; confirm low value with plasma (lab) measurement; POC underestimates by ~15% at low values

Symptomatic hypoglycemia is the high-acuity trigger for IV D10W bolus regardless of degree of hypoglycemia

Hyponatremia in adrenal insufficiency suggests AI as cause of refractory hypoglycemia

Sepsis screen if perinatal stress

Sepsis coinfection if perinatal-stress hypoglycemia → route to neonatal.early-onset-sepsis.v1

* = hard-required. Engine cannot meaningfully run until these are filled.

No severity triggers declared for this engine.

Workflow calculators

Run this disease's risk and dosing calculators inline.

TREATMENToptionalDrives dose adjustment
Loading…

Recommended regimen

Neonatal hypoglycemia — feed-first → IV dextrose → hyperinsulinism / AI agents (PES 2015 PMID 25957977; Adamkin AAP 2011 PMID 21357346; CHYLD NEJM 2015 PMID 26465984; Sugar Babies Lancet 2013 PMID 24075361)
axis: hypoglycemia_by_severity_and_etiology
Selected axis "Neonatal hypoglycemia — feed-first → IV dextrose → hyperinsulinism / AI agents (PES 2015 PMID 25957977; Adamkin AAP 2011 PMID 21357346; CHYLD NEJM 2015 PMID 26465984; Sugar Babies Lancet 2013 PMID 24075361)" by default fallback (first axis)
  • feed_first_breast_or_formula
    first line
    enteral_nutrition
    Breastfeed or formula 5-10 mL/kg orally; recheck glucose at 30 min • enteral PO • as soon as hypoglycemia identified if asymptomatic + glucose ≥ 2.0 mmol/L
    triggers: asymptomatic_hypoglycemia_glucose_above_2_mmol
    Adamkin AAP 2011 + Thornton PES 2015 first-line for asymptomatic transitional hypoglycemia; CHYLD NEJM 2015 (PMID 26465984) supports treat-to-2.6-mmol/L approach is safe and effective
  • dextrose 10% (oral gel)
    add on
    carbohydrate
    Dextrose 40% oral gel 200 mg/kg (=0.5 mL/kg) buccal massage; may repeat × 1 in 30 min • buccal_oral_gel • single dose, repeat × 1 if needed
    triggers: asymptomatic_hypoglycemia_with_feeding_response_inadequate
    Sugar Babies trial (Harris Lancet 2013 PMID 24075361) — reduced NICU admission for asymptomatic late-preterm / term hypoglycemia; first-line adjunct to feeding
    rxcui 4850
  • dextrose 10% (D10W IV bolus)
    first line
    carbohydrate_IV
    D10W 2 mL/kg IV bolus (=200 mg/kg dextrose) over 1-2 min; recheck glucose at 15-30 min • IV • single bolus; may repeat × 1 (max: max 2 mL/kg per bolus per access (D10W concentration); higher concentrations require central access)
    triggers: symptomatic_hypoglycemia, refractory_hypoglycemia_after_feeding_or_gel
    PES 2015 + Adamkin AAP 2011 — symptomatic or refractory hypoglycemia requires immediate IV correction; CHYLD demonstrated treat-to-2.6-mmol/L is neurodevelopmentally safe (NEJM 2015 PMID 26465984)
    rxcui 4850
  • dextrose 10% (D10W continuous IV infusion)
    first line
    carbohydrate_IV
    D10W IV infusion at GIR 6-8 mg/kg/min after bolus; escalate by 2 mg/kg/min q15-30 min PRN to keep POG ≥ 3.3 mmol/L • IV continuous • continuous (max: max GIR ~ 16-20 mg/kg/min via D12.5 or D15 / D20 (central access required for > D12.5); persistent need beyond this triggers hyperinsulinism workup)
    triggers: hypoglycemia_persisting_after_bolus_requires_maintenance
    PES 2015 GIR escalation; GIR > 8 mg/kg/min is hyperinsulinism red flag
    rxcui 4850
  • diazoxide
    comorbidity specific
    KATP_channel_opener
    diazoxide 8-15 mg/kg/day PO divided TID; titrate to glucose response over 48-72 h • PO • TID (max: max 15 mg/kg/day (rare 20 mg/kg/day); discontinue if no response in 5-7 d)
    triggers: confirmed_hyperinsulinism_with_inappropriately_elevated_insulin
    PES 2015 first-line for diazoxide-responsive hyperinsulinism; activates KATP channels to inhibit insulin secretion; fluid retention common (often co-give furosemide / chlorothiazide). Lactation: limited data; monitor breastfed infant for glucose and edema
    rxcui 3327
  • glucagon
    rescue
    counter_regulatory_hormone
    glucagon 0.2 mg/kg SC/IM/IV; OR continuous infusion 5-20 mcg/kg/h if persistent • SC/IM/IV (single dose) or IV continuous • single salvage dose, then bridge while IV access secured; continuous if hyperinsulinism (max: max single dose 1 mg)
    triggers: emergency_no_IV_access_neonatal_hypoglycemia, transient_bridge_for_hyperinsulinism_while_diazoxide_initiated
    Counter-regulatory bridge; requires glycogen stores so less reliable in SGA / prolonged hypoglycemia; PES 2015 + Neofax 2024
    rxcui 4832
  • octreotide
    second line
    somatostatin_analog
    octreotide 5-25 mcg/kg/day SC divided q6h; may use continuous IV infusion at same total daily dose • SC q6h or IV continuous • q6h or continuous (max: max 25 mcg/kg/day in neonate (rare 40 mcg/kg/day); risk of NEC + tachyphylaxis)
    triggers: refractory_hyperinsulinism_diazoxide_failure
    PES 2015 second-line for diazoxide-unresponsive hyperinsulinism; risk of NEC (especially in preterm) and tachyphylaxis after days; bridge to pancreatectomy in focal forms
    rxcui 7617
  • hydrocortisone
    comorbidity specific
    glucocorticoid
    hydrocortisone 5-10 mg/kg/day IV divided q6h (= 1.25-2.5 mg/kg/dose) • IV q6h • q6h (max: max 10 mg/kg/day routinely; AI crisis higher doses)
    triggers: suspected_adrenal_insufficiency_with_hypoglycemia, refractory_hypoglycemia_with_hyponatremia_or_hypotension
    PES 2015 for suspected AI; replaces deficient cortisol + counter-regulatory support. Lactation: compatible — low-dose physiologic hydrocortisone is one of the most-compatible glucocorticoids for breastfeeding (LactMed; AAP Section on Breastfeeding 2022)
    rxcui 5492

ed playbook — drug actions (3)

  1. 1. breast or formula 5-10 mL/kg PO
    5-10 mL/kg • enteral PO • as soon as identified if asymptomatic
    trigger: Asymptomatic + glucose ≥ 2.0 mmol/L
    Adamkin AAP 2011 + Thornton PES 2015
  2. 2. D10W 2 mL/kg IV bolus
    rxcui 4850
    2 mL/kg • IV • single bolus, may repeat × 1
    trigger: Symptomatic or refractory hypoglycemia
    Immediate IV correction (PES 2015)
  3. 3. glucagon 0.2 mg/kg SC/IM/IV
    rxcui 4832
    0.2 mg/kg • SC/IM/IV • single dose
    trigger: No IV access available
    Emergency bridge (PES 2015)

Auto-drafted A&P note

ed

Subjective

- Possible entry pathways: At-risk neonate (IDM / SGA / LGA / late preterm / perinatal stress) with screening glucose < 2.6 mmol/L (< 47 mg/dL) (Adamkin AAP 2011 PMID 21357346); Neonate with jitteriness / tremor / poor feeding / lethargy / hypotonia / seizure + low glucose (Thornton PES 2015 PMID 25957977); At-risk demographic — Infant of diabetic mother, SGA, LGA, late preterm (35-36 wk GA) (Adamkin AAP 2011).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Neonatal Hypoglycemia** (neonatal.hypoglycemia.v1).
Phenotype framing: Transitional hypoglycemia (<48 h, resolves with feeding). Hyperinsulinism (high insulin + low BHB / FFA at hypoglycemia; congenital / IDM / Beckwith-Wiedemann / perinatal stress). Adrenal insufficiency (congenital adrenal hyperplasia, primary AI). Hypopituitarism (low cortisol + low GH). Inborn errors of metabolism (organic acidemias, fatty acid oxidation defects, glycogen storage disease). Sepsis. Hypothermia. Polycythemia. Drug exposure (maternal beta-blocker, oral hypoglycemic).
Scope: Frame by postnatal age (transitional <48 h vs persistent >48 h per PES 2015), GA cohort (late preterm 35-36 wk vs term), birth weight percentile (SGA <10th, LGA >90th).

Plan

Regimen axis: **Neonatal hypoglycemia — feed-first → IV dextrose → hyperinsulinism / AI agents (PES 2015 PMID 25957977; Adamkin AAP 2011 PMID 21357346; CHYLD NEJM 2015 PMID 26465984; Sugar Babies Lancet 2013 PMID 24075361)**.
1. feed_first_breast_or_formula Breastfeed or formula 5-10 mL/kg orally; recheck glucose at 30 min enteral PO as soon as hypoglycemia identified if asymptomatic + glucose ≥ 2.0 mmol/L (enteral_nutrition, first line) — Adamkin AAP 2011 + Thornton PES 2015 first-line for asymptomatic transitional hypoglycemia; CHYLD NEJM 2015 (PMID 26465984) supports treat-to-2.6-mmol/L approach is safe and effective
2. dextrose 10% (oral gel) Dextrose 40% oral gel 200 mg/kg (=0.5 mL/kg) buccal massage; may repeat × 1 in 30 min buccal_oral_gel single dose, repeat × 1 if needed (carbohydrate, add on) — Sugar Babies trial (Harris Lancet 2013 PMID 24075361) — reduced NICU admission for asymptomatic late-preterm / term hypoglycemia; first-line adjunct to feeding
3. dextrose 10% (D10W IV bolus) D10W 2 mL/kg IV bolus (=200 mg/kg dextrose) over 1-2 min; recheck glucose at 15-30 min IV single bolus; may repeat × 1 (carbohydrate_IV, first line) — PES 2015 + Adamkin AAP 2011 — symptomatic or refractory hypoglycemia requires immediate IV correction; CHYLD demonstrated treat-to-2.6-mmol/L is neurodevelopmentally safe (NEJM 2015 PMID 26465984)
4. dextrose 10% (D10W continuous IV infusion) D10W IV infusion at GIR 6-8 mg/kg/min after bolus; escalate by 2 mg/kg/min q15-30 min PRN to keep POG ≥ 3.3 mmol/L IV continuous continuous (carbohydrate_IV, first line) — PES 2015 GIR escalation; GIR > 8 mg/kg/min is hyperinsulinism red flag
5. diazoxide diazoxide 8-15 mg/kg/day PO divided TID; titrate to glucose response over 48-72 h PO TID (KATP_channel_opener, comorbidity specific) — PES 2015 first-line for diazoxide-responsive hyperinsulinism; activates KATP channels to inhibit insulin secretion; fluid retention common (often co-give furosemide / chlorothiazide). Lactation: limited data; monitor breastfed infant for glucose and edema
6. glucagon glucagon 0.2 mg/kg SC/IM/IV; OR continuous infusion 5-20 mcg/kg/h if persistent SC/IM/IV (single dose) or IV continuous single salvage dose, then bridge while IV access secured; continuous if hyperinsulinism (counter_regulatory_hormone, rescue) — Counter-regulatory bridge; requires glycogen stores so less reliable in SGA / prolonged hypoglycemia; PES 2015 + Neofax 2024
7. octreotide octreotide 5-25 mcg/kg/day SC divided q6h; may use continuous IV infusion at same total daily dose SC q6h or IV continuous q6h or continuous (somatostatin_analog, second line) — PES 2015 second-line for diazoxide-unresponsive hyperinsulinism; risk of NEC (especially in preterm) and tachyphylaxis after days; bridge to pancreatectomy in focal forms
8. hydrocortisone hydrocortisone 5-10 mg/kg/day IV divided q6h (= 1.25-2.5 mg/kg/dose) IV q6h q6h (glucocorticoid, comorbidity specific) — PES 2015 for suspected AI; replaces deficient cortisol + counter-regulatory support. Lactation: compatible — low-dose physiologic hydrocortisone is one of the most-compatible glucocorticoids for breastfeeding (LactMed; AAP Section on Breastfeeding 2022)

Setting playbook (ed) — Delivery-room / transitional — IV access if symptomatic; feed-first if asymptomatic; transfer to NICU (icu) if refractory.
9. breast or formula 5-10 mL/kg PO 5-10 mL/kg enteral PO as soon as identified if asymptomatic — Asymptomatic + glucose ≥ 2.0 mmol/L (Adamkin AAP 2011 + Thornton PES 2015)
10. D10W 2 mL/kg IV bolus 2 mL/kg IV single bolus, may repeat × 1 — Symptomatic or refractory hypoglycemia (Immediate IV correction (PES 2015))
11. glucagon 0.2 mg/kg SC/IM/IV 0.2 mg/kg SC/IM/IV single dose — No IV access available (Emergency bridge (PES 2015))

Non-pharmacologic actions:
- Thermoregulation (radiant warmer)
- Skin-to-skin if stable + feeding
- Lactation support
- NICU transfer if refractory

AVOID / contraindication checks:
- Diazoxide fluid retention co give furosemide or chlorothiazide and monitor for pulmonary hypertension (PES 2015; FDA boxed warning for diazoxide pulmonary HTN in infants <2 yr 2015)
- Octreotide NEC risk especially in preterm (PES 2015)
- Glucagon requires glycogen stores unreliable in SGA or prolonged hypoglycemia (PES 2015)
- D10W bolus 2 mL per kg via peripheral line higher concentrations require central access (PES 2015)
- Hydrocortisone cortisol replacement only after critical sample drawn otherwise masks AI workup (PES 2015)
- Tight glucose control 70 to 150 mg per dL in HIE cross reference (NICHD)

Monitoring

Regimen monitoring:
- POC glucose with plasma confirmation if low
- Glucose pre-feed × first 24-48 h (q3h initially after intervention; q1h if escalating GIR)
- Critical sample at any hypoglycemic event during workup (insulin, C-peptide, BHB, FFA, lactate, ammonia, cortisol, GH)
- Sodium + potassium if hydrocortisone given (AI workup)
- Daily weight + edema check if diazoxide
- CBC + UOP if diazoxide (fluid retention)
- Echo if persistent diazoxide use (pulmonary HTN screen per FDA 2015 boxed warning)
- Neurodevelopmental follow-up at 6-12-24 mo if severe / prolonged hypoglycemia

Setting (ed) monitoring:
- Glucose at 30 min post intervention
- Continuous SpO₂ + HR
- Temperature q15 min

Follow-up plan: Pediatric endocrinology referral for confirmed hyperinsulinism, AI, hypopituitarism, or metabolic disorder. Neurodevelopmental follow-up at 6-12-24 mo (Bayley III) if severe / symptomatic / prolonged hypoglycemia. Hearing screen + family education on hypoglycemia warning signs + home glucose monitoring if discharged on diazoxide / octreotide.
- Close-out criterion: Outpatient endocrine + neurodev follow-up scheduled

Monitoring phase: Glucose pre-feed × first 24-48 h (every 3 h initially). After resolution, q4-6h × 24 h. Critical sample at any hypoglycemic event during workup. Continuous monitoring if hyperinsulinism on diazoxide / octreotide. Discharge criteria: ≥4 consecutive pre-feed glucose ≥2.6 mmol/L without intervention.

Disposition

Current setting: ed — Delivery-room / transitional — IV access if symptomatic; feed-first if asymptomatic; transfer to NICU (icu) if refractory.

Disposition criteria:
- Transfer to NICU (icu) if refractory; or admit to inpatient if stable + tolerating feeds

Escalation triggers (move to higher acuity):
- Refractory hypoglycemia after bolus + maintenance D10W → NICU + critical sample + endocrine consult
- Symptoms persist post-correction → reassess differential (sepsis, HIE, AI)

Earlier-Return Triggers

- No severity triggers declared for this engine.

Citations

- Thornton PS et al — PES 2015 Recommendations for Persistent Hypoglycemia in Neonates / Infants / Children (J Pediatr 2015 PMID 25957977); Adamkin AAP 2011 Postnatal Glucose Homeostasis (Pediatrics 2011 PMID 21357346); CHYLD (McKinlay NEJM 2015 PMID 26465984) supports treat-to-2.6-mmol/L is safe; Sugar Babies (Harris Lancet 2013 PMID 24075361) for buccal dextrose gel adjunct. [PMID:25957977](https://pubmed.ncbi.nlm.nih.gov/25957977/)
- Cited evidence (PMID 21357346) [PMID:21357346](https://pubmed.ncbi.nlm.nih.gov/21357346/)
- Cited evidence (PMID 26465984) [PMID:26465984](https://pubmed.ncbi.nlm.nih.gov/26465984/)
- Cited evidence (PMID 24075361) [PMID:24075361](https://pubmed.ncbi.nlm.nih.gov/24075361/)

Last reconciled with current guidelines: 2026-05-26.
References
  • Thornton PS et al — PES 2015 Recommendations for Persistent Hypoglycemia in Neonates / Infants / Children (J Pediatr 2015 PMID 25957977); Adamkin AAP 2011 Postnatal Glucose Homeostasis (Pediatrics 2011 PMID 21357346); CHYLD (McKinlay NEJM 2015 PMID 26465984) supports treat-to-2.6-mmol/L is safe; Sugar Babies (Harris Lancet 2013 PMID 24075361) for buccal dextrose gel adjunct. — PMID:25957977
  • Cited evidence (PMID 21357346) — PMID:21357346
  • Cited evidence (PMID 26465984) — PMID:26465984
  • Cited evidence (PMID 24075361) — PMID:24075361